Video: Barriers to results-based contracts

Despite the promise of innovative payment approaches, outdated regulations designed within the context of traditional payment models often create uncertainty for biopharmaceutical companies looking to pursue RBCs and other types of value-driven payments arrangements.

Katie KoziaraApril 17, 2018

Video: Barriers to results-based contracts

PhRMA_Value_Collaborative_Header

Research suggests results-based contracts (RBCs)—also known as value-based contracts—have the potential to lower costs for patients and the health system. According to a recent analysis, these types of arrangements can reduce copays for patients by an average of 28 percent and, if they reduce diabetes costs by five percent, could save $12 billion dollars for the United States each year.

Despite the promise of these innovative payment approaches, regulations instituted before innovative contracting approaches were developed can create uncertainty for biopharmaceutical companies looking to pursue RBCs and can discourage them from entering into these beneficial agreements.

 

 

Learn more at www.phrma.org/value-collaborative.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.